EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Long-Chain Hexafluoropropylene Oxide Homologues Impair Trophoblast Function via Integrin-Mediated FAK/PI3K/Akt Suppression and Mitochondrial Dysfunction

Yongyi Wei, Xiaodi Li, Yu Wang, Yinghua Liu, Jianyuan Wang, Yin Liu, Jianbo Jia, Bing Yan

Environment & Health · 2026-11-06

DOI: 10.1021/envhealth.6c00510 ↗
AbstractBibliografische Angaben

Abstract

Abstract Emerging per- and polyfluoroalkyl substance alternatives, including hexafluoropropylene oxide (HFPO) homologues, are increasingly detected in environmental and biological systems, yet their structure-dependent toxicity mechanisms remain poorly understood. Here, we demonstrate that long-chain HFPOs (HFPO-TA and HFPO-TeA), but not short-chain HFPO-DA or PFOA, induce pronounced toxicity in human trophoblast-like HTR-8/SVneo cells, characterized by suppressed proliferation, S-phase cell cycle arrest, and impaired migration and invasion. Transcriptomic profiling revealed selective disruption of integrin-mediated adhesion and focal adhesion signaling pathways, accompanied by activation of cellular stress responses. Consistently, long-chain HFPOs disrupted focal adhesion assembly and inhibited FAK/PI3K/Akt signaling, while simultaneously inducing mitochondrial dysfunction and excessive reactive oxygen species production. Molecular docking suggested preferential interactions between HFPO-TeA and integrin subunits, supporting a potential structure-dependent interaction mechanism. Pharmacological activation of FAK partially restored cytoskeletal organization, indicating a central role of adhesion signaling in mediating toxicity. Collectively, this study establishes a mechanistic framework linking fluorinated carbon chain length to integrin-centered adhesion signaling and mitochondrial dysfunction, advancing our understanding of how structural variation among PFAS alternatives drives cell type-specific toxicity and providing a basis for evaluating the developmental and reproductive risks of emerging PFAS substitutes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →